Bacterial NDH-1 is a key gut target of metformin mediating its antidiabetic effects
- 1Aix-Marseille Universite - IHU Mediterranee Infection
Abstract
Metformin is the first-line therapy for type 2 diabetes, yet the mechanisms underlying its glucose-lowering effects remain incompletely understood. Increasing evidence implicates gut microbiota as an important mediator of metformin action, but the bacterial targets of the drug remain poorly defined. Here, we identify bacterial NADH oxidoreductase (NDH-1), the homolog of mitochondrial complex I, as a key target of metformin. Metformin inhibited bacterial growth at millimolar concentrations and, at subinhibitory concentrations, markedly impaired carbohydrate fermentation in Escherichia coli and other NDH-1-containing bacteria. Supplementation with nicotinic acid and Mg2+; restored fermentation, whereas pyruvate bypassed the metabolic defect, implicating impaired NAD+; regeneration and disruption of metabolism upstream of pyruvate formation. Genetic analysis further established NDH-1 dependence: metformin failed to inhibit fermentation in an E. coli delta-nuoF mutant lacking functional NDH-1 but retained activity in an NDH-2-deficient delta-ndh strain. Molecular docking predicted metformin binding within the NDH-1 quinone-binding region, proximal to conserved residues involved in quinone reduction. Consistent with this mechanism, Staphylococcus aureus, which lacks NDH-1, was not affected in carbohydrate fermentation, while several gut-associated probiotic and short-chain fatty acid-producing bacteria, including Lactobacillus, Bifidobacterium, and Akkermansia muciniphila, lacked detectable NDH-1 homologs, suggesting intrinsic resistance to this metabolic effect of metformin. These findings identify bacterial NDH-1 as a metabolic target of metformin and provide a mechanistic framework for its effects on the gut microbiota. Selective inhibition of NDH-1-dependent bacteria could alter microbial substrate utilization and ecological interactions in the intestine, potentially contributing to the microbiome-mediated component of metformin's antidiabetic effects.
Related
- The chemorepellent effect of metformin limits bacterial penetration into mammalian mucus by altering bacterial motility
- Chemical profiling and in silico evaluation of a Matricaria chamomilla L. extract: exploring its antioxidant, antibacterial, antidiabetic, anti-inflammatory, and anticholinergic activities
- New depsidones from Garcinia parvifolia and their antidiabetic, anti-tyrosinase, and antioxidant activities.
- Quantifying the Provenance-to-Function Gap in Antidiabetic Peptide Prediction: Homology-Aware Evaluation and the ADP-Hybrid Baseline
- Harnessing chia seed polysaccharides for green synthesis of copper-based nanoparticles with antidiabetic and anti-inflammatory activities
BibTeX
@misc{isber2026bacterial,
title = {{Bacterial NDH-1 is a key gut target of metformin mediating its antidiabetic effects}},
author = {C. Isber and L. Hadjadj and L. Pinault and R. Razzouk and J.-M. Rolain and F. Bittar},
howpublished = {bioRxiv},
year = {2026},
month = oct,
doi = {10.64898/2026.10.02.756213},
url = {https://www.biorxiv.org/content/10.64898/2026.10.02.756213v1},
note = {CC BY-NC-ND},
}
RIS
TY - UNPB
TI - Bacterial NDH-1 is a key gut target of metformin mediating its antidiabetic effects
AU - C. Isber
AU - L. Hadjadj
AU - L. Pinault
AU - R. Razzouk
AU - J.-M. Rolain
AU - F. Bittar
PY - 2026
DA - 2026/10/02
PB - bioRxiv
DO - 10.64898/2026.10.02.756213
UR - https://www.biorxiv.org/content/10.64898/2026.10.02.756213v1
AB - Metformin is the first-line therapy for type 2 diabetes, yet the mechanisms underlying its glucose-lowering effects remain incompletely understood. Increasing evidence implicates gut microbiota as an important mediator of metformin action, but the bacterial targets of the drug remain poorly defined. Here, we identify bacterial NADH oxidoreductase (NDH-1), the homolog of mitochondrial complex I, as a key target of metformin. Metformin inhibited bacterial growth at millimolar concentrations and, at subinhibitory concentrations, markedly impaired carbohydrate fermentation in Escherichia coli and other NDH-1-containing bacteria. Supplementation with nicotinic acid and Mg2+; restored fermentation, whereas pyruvate bypassed the metabolic defect, implicating impaired NAD+; regeneration and disruption of metabolism upstream of pyruvate formation. Genetic analysis further established NDH-1 dependence: metformin failed to inhibit fermentation in an E. coli delta-nuoF mutant lacking functional NDH-1 but retained activity in an NDH-2-deficient delta-ndh strain. Molecular docking predicted metformin binding within the NDH-1 quinone-binding region, proximal to conserved residues involved in quinone reduction. Consistent with this mechanism, Staphylococcus aureus, which lacks NDH-1, was not affected in carbohydrate fermentation, while several gut-associated probiotic and short-chain fatty acid-producing bacteria, including Lactobacillus, Bifidobacterium, and Akkermansia muciniphila, lacked detectable NDH-1 homologs, suggesting intrinsic resistance to this metabolic effect of metformin. These findings identify bacterial NDH-1 as a metabolic target of metformin and provide a mechanistic framework for its effects on the gut microbiota. Selective inhibition of NDH-1-dependent bacteria could alter microbial substrate utilization and ecological interactions in the intestine, potentially contributing to the microbiome-mediated component of metformin's antidiabetic effects.
ER -